Infant Bacterial Therapeutics AB (publ)

Stockholm Stock Exchange IBT-B.ST

Infant Bacterial Therapeutics AB (publ) EBIT for the year ending December 31, 2023: USD -12.15 M

Infant Bacterial Therapeutics AB (publ) EBIT is USD -12.15 M for the year ending December 31, 2023, a -91.94% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Infant Bacterial Therapeutics AB (publ) EBIT for the year ending December 31, 2022 was USD -6.33 M, a -25.48% change year over year.
Infant Bacterial Therapeutics AB (publ) EBIT for the year ending December 31, 2021 was USD -5.04 M, a 42.86% change year over year.
Infant Bacterial Therapeutics AB (publ) EBIT for the year ending December 31, 2020 was USD -8.83 M, a -79.09% change year over year.
Infant Bacterial Therapeutics AB (publ) EBIT for the year ending December 31, 2019 was USD -4.93 M, a -7.88% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Stockholm Stock Exchange: IBT-B.ST

Infant Bacterial Therapeutics AB (publ)

CEO	Mr. Staffan Stromberg Ph.D.
IPO Date	March 29, 2016
Location	Sweden
Headquarters	Bryggargatan 10
Employees	9
Sector	Consumers Staples
Industries Baby & Childcare Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Key trends

Past 5 years